Skip to main content
Premium Trial:

Request an Annual Quote

BioMérieux Gets FDA Approval for Expanded Vitek MS Rapid Pathogen Identification

NEW YORK (GenomeWeb) – BioMérieux said today that the Vitek MS MALDI-TOF Mass Spectrometry System for rapid pathogen identification has received 510(k) clearance from the US Food and Drug Administration for the expanded identification of mycobacteria, Nocardia,and molds.

The company's database includes more than 15,000 distinct strains to provide high accuracy and enables the safe identification of the Mycobacterium tuberculosis (TB) group, the most frequent non-tuberculous mycobacteria (NTM), Nocardia, and the most medically important molds.

The company said that Vitek will offer efficient and reliable identification of these pathogens, providing clinicians with ways to manage infections such as tuberculosis, lung and bone infections, and other serious organ infections.

In order to gain FDA clearance for these new species, BioMérieux submitted information from a multi-center study consisting of 2,695 clinical isolates for 47 molds, 19 mycobacteria, and 12 Nocardia. FDA clearance of Mycobacterium species was from both solid and liquid growth media.

The competing Bruker MALDI biotyper system also received an expanded FDA approval today.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.